H&R GmbH & Co. KGaA publishes Quarterly Report for third quarter of 2025

EQS-News: H&R GmbH & Co. KGaA / Key word(s): 9 Month figures/Quarterly / Interim Statement H&R GmbH & Co. KGaA publishes Quarterly Report for third quarter of 2025  14.11.2025 / 09:38 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release

H&R GmbH & Co. KGaA: Quarterly Report for third quarter of 2025 

• Nine-month sales revenue (EUR 963.7 million) and earnings (EUR 60.5 million) fall short of prior-year figures
• Full-year forecast adjusted to lower earnings range

Salzbergen, Germany, November 14, 2025 - H&R GmbH & Co. KGaA (abbreviated: H&R KGaA; ISIN DE000A2E4T77) has confirmed its preliminary sales and earnings figures for the third quarter of 2025: From July to September 2025, the company achieved an operating result (EBITDA – consolidated earnings before interest, taxes, depreciation, and amortization, other financial income and expenses, and depreciation, amortization, and impairment losses on intangible assets and property, plant, and equipment) of EUR 20.3 million (same period last year: EUR 24.8 million). Although the third quarter of 2025 fell short of the figures for the same quarter of 2024 and the start of the year, it showed a slight improvement in earnings compared to the middle of the year. EBIT closed at EUR 5.5 million, compared to EUR 9.0 million last year. Earnings before taxes (EBT) amounted to EUR 2.6 million in the third quarter of 2025 (Q3 2024: EUR 5.8 million), while the company ended the third quarter with a slight net loss of EUR -0.7 million (Q3 2024: EUR 3.5 million). Revenues in the third quarter of the current fiscal year decreased compared to the previous year to EUR 310.6 million (Q3 2024: EUR 338.1 million).

Overview of the key figures:

in million EUR	Nine months 2025	Nine Months 2024	Diff. abs.
Sales Revenues	963.7	1,013.6	-49.9
ChemPharm REFINING	597.0	621.8	-24.8
ChemPharm SALES	351.6	370.2	-18.6
PLASTICS	27.6	36.3	-8.7
Consolidation	-12.6	-14.7	2.1
Operative Earnings (EBITDA)	60.5	65.9	-5.4
ChemPharm REFINING	40.7	35.8	4.9
ChemPharm SALES	26.8	30.8	-4.0
PLASTICS	-3.7	1.7	-5.4
Consolidation	-3.3	-2.5	-0.8
EBIT	16.4	20.6	-4.2
Earnings before Taxes	7.5	11.1	-3.6
Net Income attributable to Shareholders	-0.4	6.3	-6.7
Earnings per Share (in EUR)	-0.01	0.17	-0.18
Operative Cashflow	48.9	53.8	-4.9
Free Cashflow	8.8	17.6	-8.8
	Q3 2025	Q3 2024	Diff. abs.
Sales Revenues	310.6	338.1	-27.5
ChemPharm REFINING	191.1	204.8	-13.7
ChemPharm SALES	114.5	126.6	-12.1
PLASTICS	8.8	12.1	-3.3
Consolidation	-3.9	-5.5	1.6
Operative Earnings (EBITDA)	20.3	24.8	-4.5
ChemPharm REFINING	13.7	15.3	-1.6
ChemPharm SALES	9.0	9.7	-0.7
PLASTICS	-1.8	0.5	-2.3
Consolidation	-0.6	-0.7	0.1
EBIT	5.5	9.0	-3.5
Earnings before Taxes	2.6	5.8	-3.2
Net Income attributable to Shareholders	-0.7	3.5	-4.2
Earnings per Share (in EUR)	-0.02	0.09	-0.11
Operative Cashflow	24.3	48.3	-24.0
Free Cashflow	3.8	36.2	-32.4
	30/09/2025	31/12/2024	Diff. abs.
Balance Sheet Total	983.6	1,014.8	-31.2
Equity	452.1	468.6	-16.5
Equity Ratio (in %, difference in percentage points)	46.0	46.2	-0.2

By the middle of the year, we were already on a more cautious course and revised our forecast range to between EUR 77.0 million and EUR 90.0 million. Based on current information, the final quarter is also expected to be subdued, meaning that we anticipate achieving an overall result at the lower end of the range.